Spotlight On... FDA approves the first extended-release orally disintegrating tablet for ADHD; Matinas gets clearance to go to PhI; Israeli VC fund looking to finance drug delivery players; and more...

Neos Therapeutics hopes novel drug delivery will help newly approved Adzenys XR-ODT outcompete generic rivals in the ADHD drug market. The tablet disintegrates in the mouth and does not need to be swallowed. "This first ever FDA approval of a product using our proprietary extended-release, orally disintegrating tablet technology is an important milestone for Neos," CEO Vipin Garg said in a statement. "We believe that Adzenys XR-ODT will provide an important innovation for treatment in the ADHD market, and we intend to begin educating healthcare providers about our exciting new product immediately." The amphetamine-based tablet is similar to Shire's ($SHPG) Adderall, but boasts enhanced drug delivery. More from FierceBiotech

> Matinas BioPharma announced FDA clearance to Initiate Phase 1 Clinical Study of its candidate for the treatment of non-Tuberculous mycobacterium infections. More

> Israeli VC fund Sanara Ventures counts drug delivery devices as one of its main areas of interest. Backed by Philips ($PHG) and Teva ($TEVA), the fund is ramping up its support of innovative startups. One of its first portfolio companies makes a specialized inhaler for delivery of drugs deep into the lungs. More